Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens when used at low-dose ritonavir as a pharmacokinetic enhancer via potent inhibition of cytochrome P450 3A4 and, to a lesser extent, CYP2D6. Technically, ritonavir is a peptidomimetic inhibitor with high plasma protein binding and variable oral bioavailability that undergoes extensive hepatic metabolism to multiple oxidative and dealkylated metabolites. In clinical practice ritonavir is supplied as immediate-release tablets, oral solution and fixed-dose combinations, and is administered to increase exposure and prolong half-life of co-administered protease inhibitors or other CYP3A substrates. Pharmacokinetic considerations include nonlinear absorption at high doses, significant potential for clinically relevant drug interactions, hepatic metabolism with risk of elevated transaminases, and dose adjustments or monitoring when co-prescribing with narrow therapeutic index drugs.
Parent: Ritonavir
Parent: Ritonavir
Parent: Ritonavir
Parent: Ritonavir
Quality control of ritonavir API and finished forms generally follows ICH Q3A and pharmacopeial guidance with assay and impurity limits set to control patient exposure. Typical specification ranges used in industry are assay potency approximately 97.0 to 103.0 percent of label claim, total impurities not greater than about 1.0 percent by validated HPLC, and individual unidentified impurities generally limited to 0.1 to 0.2 percent although identified related substances may be controlled up to 0.3 to 0.5 percent depending on toxicological evaluation. Common related compounds encountered and monitored by LC MS or HPLC include the ritonavir N-oxide, dealkylated and desmethyl analogs, epimeric forms and oxidative degradants; these are typically reported and limited as individual entities and as a sum of related substances per the product master file. Residual solvents, heavy metals and water content are controlled to pharmacopeial limits and stability-indicating methods are used to characterize degradation profiles during shelf-life studies.
Ritonavir is used primarily as an HIV protease inhibitor and more commonly at low dose as a pharmacokinetic booster to increase plasma concentrations and prolong the half-life of other protease inhibitors and drugs that are metabolized by CYP3A4.
Ritonavir is included in Paxlovid to inhibit CYP3A-mediated metabolism of nirmatrelvir, the active SARS-CoV-2 protease inhibitor in Paxlovid, thereby raising and sustaining nirmatrelvir plasma concentrations to improve antiviral efficacy.
Ritonavir directly inhibits the HIV aspartyl protease enzyme, preventing proteolytic cleavage of viral polyproteins and blocking maturation of infectious virions. In booster use ritonavir inhibits cytochrome P450 3A4 enzymatic activity, reducing metabolic clearance of co-administered drugs.
Risks include clinically significant drug interactions due to potent CYP3A inhibition, hepatotoxicity with transaminase elevations, gastrointestinal adverse effects, lipid and metabolic changes, and rare cardiac conduction effects; careful review of concomitant medications and monitoring of liver function and relevant clinical parameters are required.
